Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
March 09 2023 - 8:00AM
Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage
pharmaceutical company focused on the development and
commercialization of therapies for patients with rare genetic
mitochondrial diseases, today announced that the company will
present a preclinical poster at the Society for Inherited Metabolic
Disorders (SIMD) Annual Meeting, being held in Salt Lake City,
Utah, Mar. 18-21, 2023.
Presentation PPARδ Agonist REN001 Improves
Mitochondrial Function in Skeletal Muscle: A Potential Treatment
for Primary Mitochondrial Myopathies
Date and Time Presenter: John Adams Ph.D.,
Senior Vice President, Translational Science Session: Sunday, Mar.
19, 2023, from 7:00-10:00 p.m. MST
The poster highlights the findings of pharmacological and
biochemical studies which demonstrate that mavodelpar (REN001) is a
potent and selective agonist of peroxisome proliferator-activated
receptor delta (PPARδ), resulting in increased fatty acid
metabolism. Further, mavodelpar activation of PPARδ in mice was
found to increase expression of genes involved in fatty acid
metabolism, oxidative phosphorylation, and mitochondrial
biogenesis.
Mavodelpar is currently being evaluated in a pivotal randomized
controlled clinical trial, REN001-201 (STRIDE; NCT04535609) in
adult patients with primary mitochondrial myopathies (PMM) with
confirmed mitochondrial DNA (mtDNA) defects. The poster
presentation will be available on the Presentations and
Publications page of the Reneo Pharmaceuticals website following
the event.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the
development and commercialization of therapies for patients with
rare genetic mitochondrial diseases, which are often associated
with the inability of mitochondria to produce adenosine
triphosphate (ATP). Our lead product candidate, mavodelpar, is a
potent and selective agonist of the peroxisome
proliferator-activated receptor delta (PPARδ). Mavodelpar has been
shown to increase transcription of genes involved in mitochondrial
function and increase fatty acid oxidation (FAO), and may increase
production of new mitochondria. For additional information, please
see reneopharma.com.
About Mavodelpar
Mavodelpar (REN001) is a potent and selective peroxisome
proliferator-activated receptor delta (PPARδ) agonist currently in
clinical development for two rare genetic mitochondrial diseases
that typically present with myopathy and have high unmet medical
needs: primary mitochondrial myopathies (PMM) and long-chain fatty
acid oxidation disorders (LC-FAOD). For additional information,
please see clinicaltrials.gov.
About PMM
PMM are a group of rare, genetic metabolic disorders caused by
mutations or deletions in the mitochondrial DNA (mtDNA) or nuclear
DNA (nDNA). These genetic alterations hamper the ability of
mitochondria to generate energy from nutrient sources, resulting in
energy deficits that are most pronounced in tissues with high
energy demand such as muscle, brain, and heart. The symptoms of PMM
include muscle weakness, exercise intolerance, movement disorder,
deafness, blindness, and droopy eyelids among others. The prognosis
for these disorders ranges in severity from progressive weakness to
death.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, the completion of enrollment of
clinical trials, announcement of topline data from the STRIDE
study, and the submission of marketing applications. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “plans,” “will,”
“believes,” “anticipates,” “expects,” “intends,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Reneo’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with Reneo’s business in general, and the
other risks described in Reneo’s filings with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Reneo undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
Danielle SpanglerInvestor RelationsReneo Pharmaceuticals,
Inc.dspangler@reneopharma.com
David Melamed, Ph.D.Media InquiriesRusso Partners,
LLCdavid.melamed@russopartnersllc.com
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jul 2023 to Jul 2024